Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: entasistx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $9.00 → $1.80 | Outperform → Neutral | Wedbush |
| 3/4/2022 | $6.00 → $1.80 | Buy → Neutral | HC Wainwright & Co. |
| 10/20/2021 | $5.00 → $7.00 | Outperform | BMO Capital |
| 10/19/2021 | $5.00 → $6.00 | Buy | HC Wainwright & Co. |
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced that six abstracts highlighting sulbactam-durlobactam (SUL-DUR) have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C. Details of the presentations are as follows: Oral Presentations: Title: Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva") today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis") at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022. The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 11,671,662 shares of Entasis' common stock were validly tendered and not withdrawn in the tender offer. Such shares of Entasis' common stock, upon excluding those tendered by Manoussos Perros (the "
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treatment of infections caused by Acinetobacter baumannii including carbapenem-resistant and multidrug-resistant (MDR) strains, and ETX0462 a novel, first-in-class, diazabicyclooctane with broad spectrum
Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cashPrice per share in cash represents a 50% premium to Entasis' closing price of $1.47 per share on January 31, 2022, the last date before Innoviva's original bid became publicTransaction advances Innoviva's strategy to acquire differentiated, promising healthcare assets BURLINGAME, Calif. and WALTHAM, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an advanced late-stage cl
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company presented data highlights from its pivotal Phase 3 ATTACK trial at the American Thoracic Society (ATS) annual conference, held this week from May 16-18, 2022, in San Francisco, California. The poster presentation―P628 Sulbactam-Durlobactam (SUL-DUR) Treatment Is Associated with Lower Mortality from Index Acinetobacter Infections in the Attack Phase 3 Registrational Trial―presented key data from the landmark ATTACK trial. Sulbactam-durlobac
Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023. Invested $45.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP) ("Armata"), an anti-infectives leader. Made a non-binding offer to acquire and provided $15.0 million convertible debt financing to Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an anti-infectives leader. Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2022. Gross royalty revenue
Highlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conferenceSUL-DUR NDA submission on track for mid-2022Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023 WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced its first quarter 2022 financial results and provided a business update. "During our first quarter we continued to advance our pipeline and lay the foundations of our development into a fully
WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that top-line data from the company's pivotal Phase 3 ATTACK trial was presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference, held April 23-26, 2022 in Lisbon, Portugal. In Entasis's first oral presentation, Dr. Alita Miller, PhD, Vice President, Microbiology discussed the Characterization of Acinetobacter baumannii-calcoaceticus complex (ABC) pathogens isolated at baseline from patients e
WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company will deliver multiple data presentations on sulbactam-durlobactam (SUL-DUR) at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference, to be held April 23-26, 2022 in Lisbon, Portugal. Among the seven presentations on SUL-DUR, Entasis Therapeutics will deliver two oral presentations and three posters on the topline results from its ATTACK trial—a global Phase 3 registrational tr
Phase 3 ATTACK registrational trial for sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints, NDA submission planned for mid-2022Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023Entasis' pathogen-directed platform and latest candidate ETX0462 highlighted by seminal publication in the prestigious scientific journal NatureReceipt of acquisition proposal from existing majority shareholder Innoviva, Inc. WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, toda
– Significant commercial strategy and product launch experience –– ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 – WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021. Ms. Triola will be responsible for global commercial strategy, including U.S. sales and marketing operations. "With the ATTACK Phase 3 registration clinical trial nearing completion, we are now engaged in preparing for commercialization
Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023. Invested $45.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP) ("Armata"), an anti-infectives leader. Made a non-binding offer to acquire and provided $15.0 million convertible debt financing to Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an anti-infectives leader. Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2022. Gross royalty revenue
Sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints from landmark Phase 3 ATTACK trialRobust dataset builds compelling case for SUL-DUR which if approved, could become the first, uniquely differentiated and life-saving treatment option for patients with Acinetobacter infectionsPreparing for commercialization ahead of NDA submission in mid-2022, under the leadership of newly appointed Chief Commercial Officer Anna Diaz TriolaEntasis' pathogen-directed platform and latest candidate ETX0462 highlighted by seminal publication in the prestigious scientific journal Nature WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX),
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management's prepared remarks. Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five min
SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patientsStatistically significant difference in clinical cure at Test of Cure vs. colistinFavorable safety profile with statistically significant reduction in nephrotoxicityTargeting NDA submission in mid-2022Management to host a conference call on October 19, 2021, at 8:00am ET WALTHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from its ATTACK trial―a global Phase 3 r
-Management to Host Conference Call on August 12 at 8am ET- Patient Enrollment in the ATTACK Phase 3 Registrational Trial Completed; Top-Line Data Readout Expected Early Fourth Quarter 2021SUL-DUR Launch Planning Progresses with Appointment of Anna Diaz Triola as Chief Commercial OfficerData On SUL-DUR and ETX0462 Presented at World Microbe Forum $20 Million Private Placement Transaction Completed with Innoviva WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today financial results for the second quarter 2021 an
WALTHAM, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report second quarter 2021 financial results before the market opens on August 12, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management's prepared remarks. Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes
Wedbush downgraded Entasis Therapeutics Hldg from Outperform to Neutral and set a new price target of $1.80 from $9.00 previously
HC Wainwright & Co. downgraded Entasis Therapeutics Hldg from Buy to Neutral and set a new price target of $1.80 from $6.00 previously
BMO Capital reiterated coverage of Entasis Therapeutics Hldg with a rating of Outperform and set a new price target of $7.00 from $5.00 previously
HC Wainwright & Co. reiterated coverage of Entasis Therapeutics Hldg with a rating of Buy and set a new price target of $6.00 from $5.00 previously
SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
SC 13G/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
SC 13G/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
15-12G - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)